Featured publications

  • Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma

    Authors: Haber PK; Castet F; Torres-Martin M; Andreu-Oller C; Puigvehí M; Miho M; Radu P; Dufour JF; Verslype C; Czauderna C; Marquardt JU; Galle PR; Vogel A; Bathon M; Meyer T; Labgaa I; Digklia A; Roberts LR; Mohamed Ali MA; Mínguez B; Citterio D; Mazzaferro V; Finkelmeier F; Trojan J; Özdirik B; Müller T; Schmelzle M; Bejjani A; Sung MW; Schwartz ME; Finn RS; Thung S; Villanueva A; Sia D; Llovet JM.
    Reference: Gastroenterology 2023.
  • Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

    Authors: Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM .
    Reference: Gut 2023.
  • International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance

    Authors: Singal AG; Sanduzzi-Zamparelli M; Nahon P; Ronot M; Hoshida Y; Rich N; Reig M; Vilgrain V; Marrero J; Llovet JM; Parikh ND; Villanueva A.
    Reference: Journal Of Hepatology 2023.
  • Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

    Authors: Llovet JM; Willoughby CE; Singal AG; Greten TF; Heikenwälder M; El-Serag HB; Finn RS; Friedman SL.
    Reference: Nature Reviews Gastroenterology & Hepatology 2023.
  • Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

    Authors: Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM .
    Reference: Journal Of Hepatology 2021.
  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Authors: Pfister, Dominik; Nunez, Nicolas Gonzalo; Pinyol, Roser; Govaere, Olivier; Pinter, Matthias; Szydlowska, Marta; Gupta, Revant; Qiu, Mengjie; Deczkowska, Aleksandra; Weiner, Assaf; Mueller, Florian; Sinha, Ankit; Friebel, Ekaterina; Engleitner, Thomas; Lenggenhager, Daniela; Moncsek, Anja; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; Leone, Valentina; Dudek, Michael; Yousuf, Suhail; Inverso, Donato; Singh, Indrabahadur; Teijeiro, Ana; Castet, Florian; Montironi, Carla; Haber, Philipp K.; Tiniakos, Dina; Bedossa, Pierre; Cockell, Simon; Younes, Ramy; Vacca, Michele; Marra, Fabio; Schattenberg, Jorn M.; Allison, Michael; Bugianesi, Elisabetta; Ratziu, Vlad; Pressiani, Tiziana; D'Alessio, Antonio; Personeni, Nicola; Rimassa, Lorenza; Daly, Ann K.; Scheiner, Bernhard; Pomej, Katharina; Kirstein, Martha M.; Vogel, Arndt; Peck-Radosavljevic, Markus; Hucke, Florian; Finkelmeier, Fabian; Waidmann, Oliver; Trojan, Jorg; Schulze, Kornelius; Wege, Henning; Koch, Sandra; Weinmann, Arndt; Bueter, Marco; Rossler, Fabian; Siebenhuner, Alexander; De Dosso, Sara; Mallm, Jan-Philipp; Umansky, Viktor; Jugold, Manfred; Luedde, Tom; Schietinger, Andrea; Schirmacher, Peter; Emu, Brinda; Augustin, Hellmut G.; Billeter, Adrian; Mueller-Stich, Beat; Kikuchi, Hiroto; Duda, Dan G.; Kutting, Fabian; Waldschmidt, Dirk-Thomas; Ebert, Matthias Philip; Rahbari, Nuh; Mei, Henrik E.; Schulz, Axel Ronald; Ringelhan, Marc; Malek, Nisar; Spahn, Stephan; Bitzer, Michael; Ruiz de Galarreta, Marina; Lujambio, Amaia; Dufour, Jean-Francois; Marron, Thomas U.; Kaseb, Ahmed; Kudo, Masatoshi; Huang, Yi-Hsiang; Djouder, Nabil; Wolter, Katharina; Zender, Lars; Marche, Parice N.; Decaens, Thomas; Pinato, David J.; Rad, Roland; Mertens, Joachim C.; Weber, Achim; Unger, Kristian; Meissner, Felix; Roth, Susanne; Jilkova, Zuzana Macek; Claassen, Manfred; Anstee, Quentin M.; Amit, Ido; Knolle, Percy; Becher, Burkhard; Llovet, Josep M.; Heikenwalder, Mathias;.
    Reference: Nature 2021.
  • Hepatocellular carcinoma

    Authors: Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS.
    Reference: Nature Reviews Disease Primers 2021.
  • Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

    Authors: Schulze K., Imbeaud S., Letouzé E., Alexandrov L.B., Calderaro J., Rebouissou S., Couchy G., Meiller C., Shinde J., Soysouvanh F., Calatayud A.L., Pinyol R., Pelletier L., Balabaud C., Laurent A., Blanc J.F., Mazzaferro V., Calvo F., Villanueva A., Nault J.C., Bioulac-Sage P., Stratton M.R., Llovet J.M., Zucman-Rossi J..
    Reference: Nature Genetics 2015.
  • Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

    Authors: Hoshida, Yujin; Villanueva, Augusto; Kobayashi, Masahiro; Peix, Judit; Chiang, Derek Y; Camargo, Amy; Gupta, Supriya; Moore, Jamie; Wrobel, Matthew J; Lerner, Jim; Reich, Michael; Chan, Jennifer A; Glickman, Jonathan N; Ikeda, Kenji; Hashimoto, Masaji; Watanabe, Goro; Daidone, Maria G; Roayaie, Sasan; Schwartz, Myron; Thung, Swan; Salvesen, Helga B; Gabriel, Stacey; Mazzaferro, Vincenzo; Bruix, Jordi; Friedman, Scott L; Kumada, Hiromitsu; Llovet, Josep M; Golub, Todd R.
    Reference: New England Journal Of Medicine 2008.
  • Sorafenib in Advanced Hepatocellular Carcinoma Reply

    Authors: Tabernero Caturla, Josep; Llovet, Josep M; Bruix, Jordi.
    Reference: New England Journal Of Medicine 2008.

Featured Projects

  • Molecular characterization of obesity/diabetes/NASH-related hepatocellular carcinoma

    Principal investigator: Josep M. Llovet Bayer
    Funder: Ministerio de Economia y Competitividad (MINECO)
    Code: PID2019-105378RB-100
    Duration: 01/01/2020 - 31/12/2023
  • HUNTER-Hepatocellular Carcinoma Expediter Network CRUK, AEDD, AIRC Accelerator Award.

    Principal investigator: Josep M. Llovet Bayer
    Funder: Asociación Española Contra el Cáncer (AECC) ; CRUK, AECC, AIRC Accelerator Award
    Code: AECC-Accelerator Award 2017
    Duration: 01/01/2019 - 31/12/2023
  • Mecanismos de Resistencia adquirida a sorafenib en el carcinoma hepatocelular

    Principal investigator: Josep M. Llovet Bayer
    Funder: National Health Institute, Spain. I+D Program, IIBB/IDIBAPS/CSIC (Sede o evento); National Health Institute, Spain. ; IDIBAPS - Hospital Clínic (Sede o evento)
    Code: (Grant number: SAF2016-76390-R)
    Duration: 01/01/2017 - 31/12/2020
  • Laboratori de Recerca Translacional en Oncologia Hepàtica

    Principal investigator: Josep M. Llovet Bayer
    Duration: 01/01/2022 - 31/12/2024
  • Identification of biomarkers predicting response and resistance to immunotherapy in advanced hepatocellular carcinoma

    Principal investigator: Josep M. Llovet Bayer
    Duration: 01/12/2021 - 30/11/2025